Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Follicular lymphoma: clinical features and treatment.

Tan D, Horning SJ.

Hematol Oncol Clin North Am. 2008 Oct;22(5):863-82, viii. doi: 10.1016/j.hoc.2008.07.013. Review.

PMID:
18954741
2.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G.

J Clin Oncol. 2008 Oct 1;26(28):4579-86. doi: 10.1200/JCO.2007.13.5376. Epub 2008 Jul 28.

PMID:
18662969
3.

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.

McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinkski DK, Vojdani F, Hanley KM, Garger SJ, White EL, Novak J, Barrett J, Holtz RB, Tusé D, Levy R.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10131-6. doi: 10.1073/pnas.0803636105. Epub 2008 Jul 21.

4.

Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group Hematology and Oncology Study.

J Clin Oncol. 2007 May 20;25(15):1986-92. Epub 2007 Apr 9.

PMID:
17420513
6.

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.

Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.

J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301.

PMID:
16985248
7.

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.

Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF.

J Clin Oncol. 2006 Jul 1;24(19):3107-12. Epub 2006 Jun 5.

PMID:
16754937
8.

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M.

Blood. 2005 Dec 1;106(12):3725-32. Epub 2005 Aug 25.

9.

Follicular lymphoma international prognostic index.

Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E.

Blood. 2004 Sep 1;104(5):1258-65. Epub 2004 May 4.

10.

Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.

Barrios Y, Cabrera R, Yáñez R, Briz M, Plaza A, Forés R, Fernández MN, Díaz-Espada F.

Haematologica. 2002 Apr;87(4):400-7.

11.

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.

Blood. 2002 Mar 1;99(5):1517-26.

12.

Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L.

Blood. 2000 Feb 1;95(3):783-9.

13.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP.

J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351.

PMID:
10561185
14.

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.

Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW.

Nat Med. 1999 Oct;5(10):1171-7.

PMID:
10502821
15.

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R.

J Clin Oncol. 1997 Oct;15(10):3266-74.

PMID:
9336364
16.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R.

Blood. 1997 Sep 15;90(6):2188-95.

17.

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R.

Blood. 1997 May 1;89(9):3129-35.

18.

Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma.

López-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C.

J Clin Oncol. 1994 Jul;12(7):1343-8.

PMID:
8021724
19.

Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.

Bagley CM Jr, Devita VT Jr, Berard CW, Canellos GP.

Ann Intern Med. 1972 Feb;76(2):227-34. No abstract available.

PMID:
5066691
20.

Mouse x human heterohybridomas as fusion partners with human B cell tumors.

Carroll WL, Thielemans K, Dilley J, Levy R.

J Immunol Methods. 1986 May 1;89(1):61-72.

PMID:
3084658

Supplemental Content

Support Center